ClinicalTrials.Veeva

Menu
N

Nizam's Institute of Medical Sciences | Neurology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Safinamide
Dabigatran Etexilate
Warfarin
Nintedanib
Semaglutide
Dabigatran
Eteplirsen
MOTION
LY3537982
Letrozole

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 30 total trials

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesit...

Enrolling
Chronic Kidney Disease
Obesity
Drug: Placebo
Drug: Cagrilintide

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of...

Enrolling
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Drug: Carboplatin
Drug: Pemetrexed

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Enrolling
Breast Neoplasms
Drug: Anastrozole
Drug: Tamoxifen

Part 1 (dose escalation) will evaluate the safety and tolerability of 2 doses (100 milligrams/kilogram \[mg/kg\] and 200 mg/kg) of eteplirsen in appr...

Active, not recruiting
Muscular Dystrophy, Duchenne
Drug: Eteplirsen

Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work pr...

Active, not recruiting
Chronic Kidney Disease
Type 2 Diabetes Mellitus
Drug: Finerenone (Kerendia, BAY94-8862)

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Placebo (Ziltivekimab B)
Drug: Placebo (Ziltivekimab C)

Trial sponsors

Boehringer Ingelheim logo
Lilly logo
N
Novo Nordisk logo
Population Health Research Institute (PHRI) logo
N
Adocia logo
Astellas logo
Bayer logo
B

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems